Aim Immunotech Stock Price, News & Analysis

AIM ImmunoTech announced positive results from a Phase 1/2 clinical study on its intraperitoneal chemo-immunotherapy for advanced recurrent ovarian cancer. The study, demonstrating a well-tolerated safety profile, involved 12 patients and highlighted a 55.6% overall response rate and a median overall survival of 30 months. The promising results support the advancement to a Phase 2 trial, evaluating the immunologic and clinical efficacy of a tumor-loaded αDC1 vaccine combined with cisplatin and chemokine modulation. This development is expected to provide hope for patients and create shareholder value.

AIM ImmunoTech Inc. (NYSE: American AIM) announced a live video webcast presentation on January 26, 2022, at 10:00 AM ET during the Virtual Investor 2022 Top Picks Conference. CEO Thomas K. Equels will present the company’s advancements in therapeutics for cancer, immune disorders, and viral diseases, including COVID-19. The event will feature a corporate presentation followed by an interactive Q&A session. Interested parties may submit questions live or in advance. The presentation will be accessible via the company's website, with a replay available for one year.

AIM ImmunoTech announced that safety data for its drug Ampligen was presented at the Eighth European Scientific Working Group on Influenza conference held virtually from December 4-7, 2021. The Centre for Human Drug Research shared interim results from a Phase 1 clinical study, which involved 40 healthy subjects. The study showed no severe adverse events at various dosages of Ampligen. AIM expects to receive the complete study report in January 2022. The company focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including COVID-19.

AIM ImmunoTech Inc. (NYSE American: AIM) announces CEO Thomas Equels' participation in two significant investor conferences. He will join the 'COVID-19: What’s Next in Prevention, Treatment & Diagnostics' panel at the BioFlorida Conference on December 9, 2021, at 1:45 PM EST, and also partake in the CEO Forum later that day. Additionally, Equels is scheduled to speak at the Benzinga All Access event on December 16, 2021, at 11:20 AM EST. These engagements highlight AIM's commitment to addressing urgent health issues, including COVID-19 and cancer treatments.

AIM ImmunoTech Inc. (NYSE American: AIM) reported its third quarter financial results for 2021, revealing a cash position of $53.7 million as of September 30. R&D expenses rose to $2.0 million, while G&A expenses decreased to $1.8 million, with a net loss of $3.8 million. The company is advancing multiple clinical trials for Ampligen, including a planned Phase 2 study for late-stage pancreatic cancer following positive survival data. AIM is also focused on developing treatments for COVID-19-related cognitive issues and has filed two provisional patents regarding Ampligen therapies.

AIM ImmunoTech has submitted an Investigational New Drug (IND) application for its drug Ampligen to the FDA, seeking Fast Track status for a Phase 2 study targeting late-stage pancreatic cancer. The AMP-270 trial will include around 250 participants, comparing Ampligen plus standard care against standard care alone. Early data from a prior study reported a median overall survival increase of 6.7 months for Ampligen-treated patients. AIM's application aims to enhance development and review processes for potential therapies addressing serious medical conditions.

AIM ImmunoTech Inc. (NYSE American: AIM) has released safety data from a Phase 1 clinical study of its drug Ampligen, highlighting its potential as an intranasal treatment for COVID-19. The study involved 40 healthy subjects, showing that Ampligen is generally well tolerated with no severe adverse events reported. Following these positive safety results, AIM is advancing towards a Phase 2a Human Challenge Trial and filing a Pre-Investigational New Drug application with the FDA for further studies. Results for immunological activity are expected in Q4 2021.

AIM ImmunoTech has finalized the Phase 2 study protocol for Ampligen, targeting late-stage pancreatic cancer. The company plans to submit an IND and apply for Fast Track designation by October 18, 2021. The study will be managed by Amarex Clinical Research, with the Buffett Cancer Center and Erasmus MC as lead sites. Early-access data revealed a significant increase in overall survival (19.2 months) for Ampligen-treated patients compared to a control group (12.5 months). The trial will include approximately 250 subjects and aims to assess Ampligen's efficacy when combined with standard care.

AIM ImmunoTech Inc. has announced a Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen, targeting intranasal prophylaxis against respiratory viruses. Conducted by hVIVO, the trial is set to enroll 64 healthy participants, who will be exposed to human rhinovirus and influenza A to evaluate Ampligen's efficacy. The study is pending approval from the Oxford Research Ethics Committee, with expectations to start in Q4 2021. A successful trial could position Ampligen as a viable prophylactic against current and future viral threats.